Tumor Screening Platform
Total Trials
2
As Lead Sponsor
1
As Collaborator
Total Enrollment
50
NCT03371992
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC
Phase: Early Phase 1
Role: Lead Sponsor
Start: Mar 9, 2018
Completion: Jun 30, 2021
NCT05332925
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
Phase: N/A
Role: Collaborator
Start: Jul 21, 2022
Completion: Feb 28, 2027
Loading map...